If you or your child gets ADHD medication through a video visit, you may have seen headlines about a December 31, 2026 deadline and wondered whether your next refill is at risk. It is a fair worry. Millions of people rely on telehealth to reach a psychiatrist, and the rules behind it have been temporary for more than six years.
This guide explains, in plain English, what is changing, who is affected, what is still uncertain, and what you can do now so your care is not interrupted.
Quick Answer
Right now, yes. Under a federal extension running through December 31, 2026, a DEA-registered clinician can prescribe Schedule II–V controlled medications, including ADHD stimulants such as Adderall, Vyvanse and Ritalin, after a live video visit, without a prior in-person exam. What happens on January 1, 2027 depends on whether the DEA finalizes a permanent rule or issues another extension. As of November 19, 2026, we found no announcement of either. Medications that are not controlled substances, such as most antidepressants, are not affected.
Key Takeaways
- The current federal telehealth prescribing flexibilities for controlled medications expire December 31, 2026.
- The DEA sent its final “special registration” rule to White House review on August 25, 2026, but the final text has not been made public.
- If nothing replaces the flexibilities, the older in-person evaluation requirement would apply to new telehealth controlled-substance prescriptions.
- Non-controlled medications (SSRIs, bupropion, lithium, most antipsychotics, non-stimulant ADHD options) follow normal telehealth rules.
- State rules can be stricter than federal rules, so your state and your prescriber’s setup matter.
Why Is There a Deadline at All?
The deadline traces back to a 2008 federal law called the Ryan Haight Online Pharmacy Consumer Protection Act. In general, it requires a clinician to conduct at least one in-person medical evaluation before prescribing a controlled substance, unless an exception applies. Lawmakers wrote it to curb illegal online pharmacies.
In March 2020, during the COVID-19 emergency, the DEA waived that requirement so people could keep getting care at home. When the public health emergency ended, regulators did not let the waiver lapse. Instead, the DEA and HHS issued a series of temporary extensions. The fourth and current one covers January 1 through December 31, 2026, and was announced to give regulators time to finish permanent rules, including a proposed “Special Registration for Telemedicine.”
That is why this keeps coming back every year: the flexibility was never made permanent.
Which Medications Are Affected?
Only controlled substances are covered by these rules. Telehealth prescribing of non-controlled drugs does not involve the DEA’s in-person requirement.
| Likely affected (controlled) | Usually not affected (non-controlled) |
|---|---|
| ADHD stimulants: Adderall, Vyvanse, Ritalin, Concerta | SSRIs and SNRIs (Lexapro, Zoloft, Prozac) |
| Benzodiazepines: Xanax, Klonopin, Ativan | Bupropion (Wellbutrin) |
| Some sleep medications | Lithium and most mood stabilizers |
| Most antipsychotics | |
| Non-stimulant ADHD options (atomoxetine, guanfacine) |
Buprenorphine for opioid use disorder is handled under a separate final rule issued in January 2025, so it follows its own path.
If you are comparing options, our guides on common types of psychiatric medication and side effects of psychiatric medications explain how these drug classes differ.
What Happens on January 1, 2027? Three Possible Outcomes
Nobody outside the agencies can say for certain, but the realistic scenarios are:
1. A permanent “special registration” rule is finalized. The DEA submitted its final rule to the Office of Information and Regulatory Affairs on August 25, 2026. The review office typically has up to 90 days, with a possible 30-day extension. The January 2025 proposal described three types of special registration and included requirements around practice standards, prescription drug monitoring checks, identity verification, record retention, data reporting and limits on Schedule II prescribing. The final version may differ, so watch for the published text.
2. Another temporary extension. The DEA has done this four times, often close to the deadline. The last one was published on December 31, 2025, which left patients and clinicians waiting until the final day.
3. The flexibilities lapse. The Ryan Haight Act’s in-person requirement would apply again. New telehealth patients would need an in-person evaluation before receiving a controlled-substance prescription. Patients who have already had an in-person exam with their prescriber are generally in a different position than those whose care began entirely by video, and some of the latter group could be asked to come in before a renewal. Your prescriber is the right person to confirm how this applies to you.
This is not legal advice, and the situation is changing. Check with your prescriber for the latest.
Does This Affect Maryland, Florida and North Carolina Patients Differently?
Federal rules are the floor, not the ceiling. States can add their own conditions. In Maryland, for example, a prescriber needs a state Controlled Dangerous Substances registration in addition to their DEA registration, and must be registered with the state prescription drug monitoring program, which runs through CRISP. Other states have their own prescribing, licensing and monitoring requirements.
The practical takeaway: telehealth availability depends on where you are physically located during the visit and on where your clinician is licensed. TruMediq offers telehealth in Maryland, Florida and North Carolina, subject to provider availability and the patient’s location. See our areas we cover page, or the pages for Maryland and Florida, for local detail.
How to Prepare Now: A Practical Checklist
You do not need to panic, but a few steps now can prevent a gap in treatment.
- Ask your prescriber directly. Questions to ask: “Have I had an in-person evaluation with you?” “If the rules change on January 1, what would my next refill require?” “How far in advance do you need to see me?”
- Do not stretch or skip doses. Cutting back to make a prescription last longer can cause symptoms to return and, with some medications, withdrawal effects. Medication changes should be planned with your prescriber, as we explain in how to balance medication and therapy.
- Keep your records handy. A current medication list, previous diagnoses, pharmacy details and prior evaluations make any in-person visit faster.
- Plan refills early. Controlled medications generally cannot be refilled in advance of a set schedule, so talk to your clinician about timing around late December and early January.
- Review your insurance. If you may need an in-person visit, confirm coverage in advance. Our fees and insurance page explains how to verify benefits, and our post on insurance coverage for ADHD testing and treatment covers common questions.
- Consider a hybrid plan. One in-person visit with a local psychiatrist, followed by video follow-ups, is a common approach that works under both current and older rules.
Telehealth ADHD Care Is More Than a Prescription
It helps to remember that ADHD treatment is rarely just a pill. A thorough evaluation looks at attention, organization, restlessness and impulsivity across settings, and considers sleep, anxiety and other explanations. Plans can include behavioral strategies, coaching, therapy and, when appropriate, medication. Stimulants are one option; non-stimulant medications are another, and the right choice depends on the person.
That is why at TruMediq a stimulant prescription is not guaranteed at a first visit; it depends on the evaluation. Our ADHD care page outlines how evaluations work for children, teens and adults, and our guides to ADHD in adults and ADHD in women explain why it is so often missed. If you are new to virtual care, what is telepsychiatry and how telepsychiatry works and who it helps are good starting points. For families, the child psychiatry page explains how parents are involved in a young person’s care.
When In-Person Care Is Still the Better Choice
Even when telehealth is allowed, it is not right for everyone. In-person care may be a better fit if you have severe symptoms that need close supervision, if you are in crisis, if you lack a private space or reliable internet, or if your clinician needs a physical assessment. If you are ever in immediate danger or thinking about harming yourself, call or text 988 (the Suicide & Crisis Lifeline) or go to the nearest emergency room.
Many people do best with a mix: video visits for routine follow-ups and an office visit when it matters. TruMediq’s office in Catonsville, Maryland offers in-person appointments, and see our psychiatrist in Catonsville page for details.
Frequently Asked Questions
Can I get Adderall prescribed through telehealth in 2026?
Yes, under the current federal extension, a DEA-registered clinician can prescribe Adderall after a live video visit without a prior in-person exam, through December 31, 2026. The clinician must still decide the prescription is medically appropriate, and state rules still apply.
What happens to my ADHD prescription if the DEA flexibilities expire?
If no extension or permanent rule replaces them, the in-person evaluation requirement would apply to controlled-substance prescriptions by telehealth. Patients who have already had an in-person exam with their prescriber are generally in a different position than patients who have only ever been seen by video. Ask your prescriber how your care would be handled.
Is the DEA’s telemedicine special registration final?
Not as of November 19, 2026. It was proposed in January 2025, and a final version went to White House review on August 25, 2026. The final text has not been public.
Are antidepressants and anxiety medications affected?
Most are not. Antidepressants such as SSRIs and bupropion, lithium and most antipsychotics are not controlled substances. Benzodiazepines are controlled, so they are covered by these rules.
Do I need to go in person to start ADHD treatment?
Not under the current federal extension, but your state, your prescriber’s policies and your own clinical situation can still call for an in-person visit. Some people prefer to start in person.
Will my insurance cover a telehealth or in-person visit?
Coverage depends on your plan. Check your benefits, ask whether a referral is needed, and call the practice to confirm they accept your insurance. See our fees and insurance page.
Get Support Without the Guesswork
Rules like these can feel like they are changing under your feet. You do not have to figure it out alone. TruMediq offers psychiatric evaluations, medication management and ongoing follow-up in person in Catonsville, Maryland and by telehealth in Maryland, Florida and North Carolina, with care for children, teens and adults.
Ready to talk? Book through Zocdoc, call 1-800-954-4558, or submit an intake request. You can also learn more about our team or explore all treatments and services.
Disclaimer: This article is for general education and is not medical or legal advice. Telehealth prescribing rules are changing; confirm current requirements with your prescriber and the DEA.